Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
Insulin "Icodec" Could Be a Diabetes Breakthrough with a Half Life of Over 8 Days - The Diabetes Site News
Novo Nordisk Once-Weekly Insulin Comparable to Daily Injections - Type 2 Nation
Novo Scores Phase III Insulin Icodec Win, Potentially Strengthening Market Position | BioSpace
Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans | Journal of Medicinal Chemistry
Novo Nordisk achieve headline results with icodec insulin | pharmaphorum
Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment | NEJM
Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes - Philis‐Tsimikas - Diabetes, Obesity and Metabolism - Wiley Online Library
Novo Nordisk bolstered by another late-stage trial of once weekly insulin icodec (NVO) | Seeking Alpha
Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans | Journal of Medicinal Chemistry
Novo Nordisk tees up phase 3 trial for once-weekly insulin | Fierce Biotech
Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued - MidgardFinance.com
Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans | Journal of Medicinal Chemistry
Once-Weekly Insulin Icodec Promising for Type 2 Diabetes - Consumer Health News | HealthDay
Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
